-
1
-
-
0032546266
-
Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL
-
Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR (1998a) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16, 1383-1390.
-
(1998)
Oncogene
, vol.16
, pp. 1383-1390
-
-
Amarante-Mendes, G.P.1
McGahon, A.J.2
Nishioka, W.K.3
Afar, D.E.4
Witte, O.N.5
Green, D.R.6
-
2
-
-
0032032270
-
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
-
Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K (1998b) Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91, 1700-1705.
-
(1998)
Blood
, vol.91
, pp. 1700-1705
-
-
Amarante-Mendes, G.P.1
Naekyung Kim, C.2
Liu, L.3
Huang, Y.4
Perkins, C.L.5
Green, D.R.6
Bhalla, K.7
-
3
-
-
0028910894
-
The single cell gel electrophoresis assay for induced DNA damage (comet assay): Measurement of tail length and moment
-
Ashby JA, Tinwell H, Lefevre PA, Browne MA (1995) The single cell gel electrophoresis assay for induced DNA damage (comet assay): Measurement of tail length and moment. Mutagenesis 10, 85-90.
-
(1995)
Mutagenesis
, vol.10
, pp. 85-90
-
-
Ashby, J.A.1
Tinwell, H.2
Lefevre, P.A.3
Browne, M.A.4
-
4
-
-
0029131231
-
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
-
Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86, 1148-1158.
-
(1995)
Blood
, vol.86
, pp. 1148-1158
-
-
Bedi, A.1
Barber, J.P.2
Bedi, G.C.3
El-Deiry, W.S.4
Sidransky, D.5
Vala, M.S.6
Akhtar, A.J.7
Hilton, J.8
Jones, R.J.9
-
5
-
-
0037140386
-
Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine
-
Blasiak J, Gloc E, Wozniak K, Mlynarski W, Stolarska M, Skorski T, Majsterek I (2002) Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact 149, 1-18.
-
(2002)
Chem Biol Interact
, vol.149
, pp. 1-18
-
-
Blasiak, J.1
Gloc, E.2
Wozniak, K.3
Mlynarski, W.4
Stolarska, M.5
Skorski, T.6
Majsterek, I.7
-
6
-
-
0031059558
-
Idarubicin: A brief overview on pharmacology and clinical use
-
Borchmann P, Hubel K, Schnell R, Engert A (1997) Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol 35, 80-83.
-
(1997)
Int J Clin Pharmacol
, vol.35
, pp. 80-83
-
-
Borchmann, P.1
Hubel, K.2
Schnell, R.3
Engert, A.4
-
7
-
-
0030031766
-
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
-
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon HB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56, 100-104.
-
(1996)
Cancer Res
, vol.56
, pp. 100-104
-
-
Buchdunger, E.1
Zimmermann, J.2
Mett, H.3
Meyer, T.4
Muller, M.5
Druker, B.J.6
Lydon, H.B.7
-
8
-
-
0034234211
-
Cooperative effects of genes controlling the G(2)/M checkpoint
-
Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B (2000) Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14, 1584-1588.
-
(2000)
Genes Dev
, vol.14
, pp. 1584-1588
-
-
Chan, T.A.1
Hwang, P.M.2
Hermeking, H.3
Kinzler, K.W.4
Vogelstein, B.5
-
9
-
-
24044548990
-
Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants
-
Corradini F, Cesi V, Bartella V, Pani E, Bussolari R, Candini O, Calabretta B (2005) Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants. J Biol Chem 280, 30254-30262.
-
(2005)
J Biol Chem
, vol.280
, pp. 30254-30262
-
-
Corradini, F.1
Cesi, V.2
Bartella, V.3
Pani, E.4
Bussolari, R.5
Candini, O.6
Calabretta, B.7
-
10
-
-
0025117392
-
Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr/abl protein
-
Daley GQ, Van Etten RA, Baltimore D (1990) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr/abl protein. Science 247, 824-830.
-
(1990)
Science
, vol.247
, pp. 824-830
-
-
Daley, G.Q.1
Van Etten, R.A.2
Baltimore, D.3
-
11
-
-
0033782402
-
BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32)
-
De Angeli C, Gandini D, Cuneo A, Moretti S, Bigoni R, Roberti MG, Bardi A, Castoldi GL, del Senno L (2000) BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32). Haematologica 85, 913-921.
-
(2000)
Haematologica
, vol.85
, pp. 913-921
-
-
De Angeli, C.1
Gandini, D.2
Cuneo, A.3
Moretti, S.4
Bigoni, R.5
Roberti, M.G.6
Bardi, A.7
Castoldi, G.L.8
del Senno, L.9
-
12
-
-
0041466445
-
Specific targeted therapy of chronic myelogenous leukemia with imatinib
-
Deininger MW, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55, 401-423.
-
(2003)
Pharmacol Rev
, vol.55
, pp. 401-423
-
-
Deininger, M.W.1
Druker, B.J.2
-
13
-
-
0035810142
-
Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001b) Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344, 1038-1042.
-
(2001)
N Engl J Med
, vol.344
, pp. 1038-1042
-
-
Druker, B.J.1
Sawyers, C.L.2
Kantarjian, H.3
Resta, D.J.4
Reese, S.F.5
Ford, J.M.6
Capdeville, R.7
Talpaz, M.8
-
14
-
-
0035810147
-
Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia
-
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001a) Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031-1037.
-
(2001)
N Engl J Med
, vol.344
, pp. 1031-1037
-
-
Druker, B.J.1
Talpaz, M.2
Resta, D.J.3
Peng, B.4
Buchdunger, E.5
Ford, J.M.6
Lydon, N.B.7
Kantarjian, H.8
Capdeville, R.9
Ohno-Jones, S.10
Sawyers, C.L.11
-
15
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR/ABL positive cells
-
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR/ABL positive cells. Nat Med 2, 561-566.
-
(1996)
Nat Med
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
Zimmermann, J.7
Lydon, N.B.8
-
16
-
-
0038172523
-
Chronic myeloid leukemia in the imatinib era
-
Druker BJ (2003) Chronic myeloid leukemia in the imatinib era. Semin Hematol 40, 50-58.
-
(2003)
Semin Hematol
, vol.40
, pp. 50-58
-
-
Druker, B.J.1
-
17
-
-
0028264824
-
Modelling the process of drug resistance
-
Goldie JH (1994) Modelling the process of drug resistance. Lung Cancer 10, 91-96.
-
(1994)
Lung Cancer
, vol.10
, pp. 91-96
-
-
Goldie, J.H.1
-
18
-
-
28544450495
-
Selecting and deselecting imatinib-resistant clones: Observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
-
Gruber FX, Lamark T, Anonli TA, Sovershaev MA, Olsen M, Gedde-Dahl T, Hjort-Hansen H, Skogen B (2005) Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 19, 2159-2165.
-
(2005)
Leukemia
, vol.19
, pp. 2159-2165
-
-
Gruber, F.X.1
Lamark, T.2
Anonli, T.A.3
Sovershaev, M.A.4
Olsen, M.5
Gedde-Dahl, T.6
Hjort-Hansen, H.7
Skogen, B.8
-
19
-
-
0035120788
-
Engagement of the CrkL adaptor in interferon alpha signalling in BCR/ABL-expressing cells
-
Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC (2001) Engagement of the CrkL adaptor in interferon alpha signalling in BCR/ABL-expressing cells. Br J Haematol 112, 327-336.
-
(2001)
Br J Haematol
, vol.112
, pp. 327-336
-
-
Grumbach, I.M.1
Mayer, I.A.2
Uddin, S.3
Lekmine, F.4
Majchrzak, B.5
Yamauchi, H.6
Fujita, S.7
Druker, B.8
Fish, E.N.9
Platanias, L.C.10
-
20
-
-
0028889948
-
Molecular mechanisms of drug resistance in tumours
-
Harrison DJ (1995) Molecular mechanisms of drug resistance in tumours. J Pathol, 175, 7-12.
-
(1995)
J Pathol
, vol.175
, pp. 7-12
-
-
Harrison, D.J.1
-
21
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2106.
-
(2002)
Leukemia
, vol.16
, pp. 2190-2106
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
La Rosee, P.4
Muller, M.C.5
Lahaye, T.6
Hanfstein, B.7
Schoch, C.8
Cross, N.C.9
Berger, U.10
Gschaidmeier, H.11
Druker, B.J.12
Hehlmann, R.13
-
22
-
-
0344951307
-
Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: Role in drug resistance?
-
Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T ( 2003) Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leukemia Res 27, 267-273.
-
(2003)
Leukemia Res
, vol.27
, pp. 267-273
-
-
Hoser, G.1
Majsterek, I.2
Romana, D.L.3
Slupianek, A.4
Blasiak, J.5
Skorski, T.6
-
23
-
-
0030580947
-
The comet assay: Mechanisms and technical considerations
-
Klaude M, Eriksson S, Nygren J, Ahnstrom G (1996) The comet assay: mechanisms and technical considerations. Mutat Res 12, 89-96.
-
(1996)
Mutat Res
, vol.12
, pp. 89-96
-
-
Klaude, M.1
Eriksson, S.2
Nygren, J.3
Ahnstrom, G.4
-
24
-
-
0037672877
-
Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics
-
Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Int Med 138, 819-830.
-
(2003)
Ann Int Med
, vol.138
, pp. 819-830
-
-
Kurzrock, R.1
Kantarjian, H.M.2
Druker, B.J.3
Talpaz, M.4
-
25
-
-
41449104648
-
1 expression in a leukemia cell line and its doxorubicine-resistant variant by topoisomerase II inhibitors
-
1 expression in a leukemia cell line and its doxorubicine-resistant variant by topoisomerase II inhibitors. Biochemical Pharmacology 60, 1832-1828.
-
(2000)
Biochemical Pharmacology
, vol.60
, pp. 1832-1828
-
-
Laroche-Clary, A.1
Larrue, A.2
Robert, J.3
-
26
-
-
15844385545
-
Ku80-deficient cells exhibit excess degradation of Extrachromosomal DNA
-
Liang F, Jasin M (1996) Ku80-deficient cells exhibit excess degradation of Extrachromosomal DNA. J Biol Chem 271, 14405-14411.
-
(1996)
J Biol Chem
, vol.271
, pp. 14405-14411
-
-
Liang, F.1
Jasin, M.2
-
27
-
-
0025348013
-
Tyrosine kinse activity and transformation potency of BCR/ABL oncogene products
-
Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinse activity and transformation potency of BCR/ABL oncogene products. Science 247, 1079-1082.
-
(1990)
Science
, vol.247
, pp. 1079-1082
-
-
Lugo, T.G.1
Pendergast, A.M.2
Muller, A.J.3
Witte, O.N.4
-
28
-
-
0036343687
-
Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?
-
Majsterek I, Blasiak J, Mlynarski W, Hoser G, Skorski T (2002) Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biol Int 26, 363-370.
-
(2002)
Cell Biol Int
, vol.26
, pp. 363-370
-
-
Majsterek, I.1
Blasiak, J.2
Mlynarski, W.3
Hoser, G.4
Skorski, T.5
-
29
-
-
0142093206
-
TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin
-
Majsterek I, Slupianek A, Blasiak J (2003) TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin. Anti-Cancer Drugs 14, 625-631.
-
(2003)
Anti-Cancer Drugs
, vol.14
, pp. 625-631
-
-
Majsterek, I.1
Slupianek, A.2
Blasiak, J.3
-
30
-
-
1342308086
-
ABL-fusion oncoproteins activate multi-pathway of DNA repair: Role in drug resistance?
-
Majsterek I, Slupianek A, Hoser G, Skorski T, Blasiak J (2004) ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Biochemie 86, 53-65.
-
(2004)
Biochemie
, vol.86
, pp. 53-65
-
-
Majsterek, I.1
Slupianek, A.2
Hoser, G.3
Skorski, T.4
Blasiak, J.5
-
31
-
-
0032924293
-
-
Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y (1999) v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells Int J Cancer 80, 731-737.
-
Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y (1999) v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells Int J Cancer 80, 731-737.
-
-
-
-
32
-
-
0036139993
-
STI571: A paradigm of new agents for cancer therapeutics
-
Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ (2002) STI571: a paradigm of new agents for cancer therapeutics. Clin Oncol 20, 325-334.
-
(2002)
Clin Oncol
, vol.20
, pp. 325-334
-
-
Mauro, M.J.1
O'Dwyer, M.2
Heinrich, M.C.3
Druker, B.J.4
-
33
-
-
0036682301
-
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
-
Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62, 4236-4243.
-
(2002)
Cancer Res
, vol.62
, pp. 4236-4243
-
-
Nagar, B.1
Bornmann, W.G.2
Pellicena, P.3
Schindler, T.4
Veach, D.R.5
Miller, W.T.6
Clarkson, B.7
Kuriyan, J.8
-
34
-
-
0344626926
-
Structural basis for the autoinhibition of c-Abl tyrosine kinase
-
Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W,Clarkson B, Superti-Furga G, Kuriyan J (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871.
-
(2003)
Cell
, vol.112
, pp. 859-871
-
-
Nagar, B.1
Hantschel, O.2
Young, M.A.3
Scheffzek, K.4
Veach, D.5
Bornmann, W.6
Clarkson, B.7
Superti-Furga, G.8
Kuriyan, J.9
-
35
-
-
0029802284
-
BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block
-
Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF (1996) BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13, 2225-2234.
-
(1996)
Oncogene
, vol.13
, pp. 2225-2234
-
-
Nishii, K.1
Kabarowski, J.H.2
Gibbons, D.L.3
Griffiths, S.D.4
Titley, I.5
Wiedemann, L.M.6
Greaves, M.F.7
-
36
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL,Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R,Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348, 994-1004.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
Cornelissen, J.J.7
Fischer, T.8
Hochhaus, A.9
Hughes, T.10
Lechner, K.11
Nielsen, J.L.12
Rousselot, P.13
Reiffers, J.14
Saglio, G.15
Shepherd, J.16
Simonsson, B.17
Gratwohl, A.18
Goldman, J.M.19
Kantarjian, H.20
Taylor, K.21
Verhoef, G.22
Bolton, A.E.23
Capdeville, R.24
Druker, B.J.25
more..
-
37
-
-
0028200221
-
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
-
Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ ( 1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells, Oncogene 9, 1829-1838.
-
(1994)
Oncogene
, vol.9
, pp. 1829-1838
-
-
Pietras, R.J.1
Fendly, B.M.2
Chazin, V.R.3
Pegram, M.D.4
Howell, S.B.5
Slamon, D.J.6
-
38
-
-
0031946385
-
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
-
Sattler M, Salgia R (1998) Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Leukemia 12, 637-644.
-
(1998)
Leukemia
, vol.12
, pp. 637-644
-
-
Sattler, M.1
Salgia, R.2
-
39
-
-
0031840440
-
Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells
-
Senechal K, Heaney C, Druker B, Sawyers CL (1998) Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells. Mol Cell Biol 18, 5082-5090.
-
(1998)
Mol Cell Biol
, vol.18
, pp. 5082-5090
-
-
Senechal, K.1
Heaney, C.2
Druker, B.3
Sawyers, C.L.4
-
40
-
-
0023919963
-
A simple technique for quantitation of low levels of DNA damage in individual cells
-
Singh NP, McCoy T, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175, 184-192.
-
(1988)
Exp Cell Res
, vol.175
, pp. 184-192
-
-
Singh, N.P.1
McCoy, T.2
Tice, R.R.3
Schneider, E.L.4
-
41
-
-
0000507213
-
Differential responses of proliferating versus quiescent cells to adriamycin
-
Siu WY, Arooz T, Poon RYC (1999) Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 250, 131-141.
-
(1999)
Exp Cell Res
, vol.250
, pp. 131-141
-
-
Siu, W.Y.1
Arooz, T.2
Poon, R.Y.C.3
-
42
-
-
20544441981
-
BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin
-
Slupianek A, Gurdek E, Koptyra M, Nowicki MO, Siddiqui KM, Groden J, Skorski T (2005) BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin. Oncogene 24, 3914-3922.
-
(2005)
Oncogene
, vol.24
, pp. 3914-3922
-
-
Slupianek, A.1
Gurdek, E.2
Koptyra, M.3
Nowicki, M.O.4
Siddiqui, K.M.5
Groden, J.6
Skorski, T.7
-
43
-
-
0036261727
-
Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis
-
Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T (2002) Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis. Mol Cell Biol 22, 4189-4201.
-
(2002)
Mol Cell Biol
, vol.22
, pp. 4189-4201
-
-
Slupianek, A.1
Hoser, G.2
Majsterek, I.3
Bronisz, A.4
Malecki, M.5
Blasiak, J.6
Fishel, R.7
Skorski, T.8
-
44
-
-
30344461008
-
BCR/ABL modifies the kinetics and fidelity of DNA double-strand break repair in hematopoetic cells
-
Slupianek A, Nowicki MO, Koptyra M, Skorski T (2006) BCR/ABL modifies the kinetics and fidelity of DNA double-strand break repair in hematopoetic cells. DNA Repair 5, 243-250.
-
(2006)
DNA Repair
, vol.5
, pp. 243-250
-
-
Slupianek, A.1
Nowicki, M.O.2
Koptyra, M.3
Skorski, T.4
-
45
-
-
0034760095
-
BCR/ABL regulates mammalian RecA homologs resulting in drug resistance
-
Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T (2001) BCR/ABL regulates mammalian RecA homologs resulting in drug resistance. Mol Cell 8, 795-806.
-
(2001)
Mol Cell
, vol.8
, pp. 795-806
-
-
Slupianek, A.1
Schmutte, C.2
Tombline, G.3
Nieborowska-Skorska, M.4
Hoser, G.5
Nowicki, M.O.6
Pierce, A.J.7
Fishel, R.8
Skorski, T.9
-
46
-
-
0038700985
-
Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies
-
Tipping AJ, Melo JV (2003) Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. Semin. Hematol 40, 83-91.
-
(2003)
Semin. Hematol
, vol.40
, pp. 83-91
-
-
Tipping, A.J.1
Melo, J.V.2
-
47
-
-
0029987450
-
Targeted disruption of the Rad51 gene leads to lethality in embryonic mice
-
Tsuzuki T, Fujii Y, Sakumi K, Tominaga Y, Nakao K, Sekiguchi M, Matsushiro A, Yoshimura Y, Morita T (1996) Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 93, 6236-6240.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 6236-6240
-
-
Tsuzuki, T.1
Fujii, Y.2
Sakumi, K.3
Tominaga, Y.4
Nakao, K.5
Sekiguchi, M.6
Matsushiro, A.7
Yoshimura, Y.8
Morita, T.9
-
48
-
-
10344225622
-
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein
-
Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, Zhang J, Chen GQ, Chen SJ, Chen Z (2004) Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104, 4219-4225.
-
(2004)
Blood
, vol.104
, pp. 4219-4225
-
-
Yin, T.1
Wu, Y.L.2
Sun, H.P.3
Sun4
GL, D.Y.5
Wang, K.K.6
Zhang, J.7
Chen, G.Q.8
Chen, S.J.9
Chen, Z.10
-
49
-
-
0141799739
-
Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro
-
Zhang P, Gao WY, Turner S, Ducatman BS (2003) Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2, 1.
-
(2003)
Mol Cancer
, vol.2
, pp. 1
-
-
Zhang, P.1
Gao, W.Y.2
Turner, S.3
Ducatman, B.S.4
|